Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Assets (2016 - 2025)

Historic Assets for Theravance Biopharma (TBPH) over the last 13 years, with Q3 2025 value amounting to $415.5 million.

  • Theravance Biopharma's Assets rose 1666.78% to $415.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $415.5 million, marking a year-over-year increase of 1666.78%. This contributed to the annual value of $354.2 million for FY2024, which is 728.75% down from last year.
  • Theravance Biopharma's Assets amounted to $415.5 million in Q3 2025, which was up 1666.78% from $426.0 million recorded in Q2 2025.
  • In the past 5 years, Theravance Biopharma's Assets registered a high of $763.5 million during Q3 2022, and its lowest value of $343.6 million during Q1 2025.
  • Moreover, its 5-year median value for Assets was $382.0 million (2023), whereas its average is $425.2 million.
  • Its Assets has fluctuated over the past 5 years, first skyrocketed by 8940.19% in 2022, then tumbled by 4582.94% in 2023.
  • Theravance Biopharma's Assets (Quarter) stood at $374.8 million in 2021, then skyrocketed by 62.05% to $607.4 million in 2022, then plummeted by 37.11% to $382.0 million in 2023, then dropped by 7.29% to $354.2 million in 2024, then increased by 17.31% to $415.5 million in 2025.
  • Its Assets was $415.5 million in Q3 2025, compared to $426.0 million in Q2 2025 and $343.6 million in Q1 2025.